SCHEMBL16193121

SCHEMBL16193121

Cc1nc2ccc(N3CC[C@H](N(C)C)C3)nn2c1C(=O)Nc1ccncn1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 1/20 0.38
▸ HRH4 Q9H3N8 3/20 0.38
▸ HRH3 Q9Y5N1 3/20 0.38
▸ MAP4K4 O95819 2/20 0.38
▸ AAK1 Q2M2I8 4/20 0.36
▸ KLKB1 P03952 1/20 0.35
▸ KLK1 P06870 1/20 0.35
▸ MAPK8 P45983 1/20 0.35
▸ MAPK10 P53779 1/20 0.35
▸ BTK Q06187 1/20 0.35
▸ MRGPRX2 Q96LB1 1/20 0.35
▸ WNT1 P04628 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ ADORA2A P29274 2/20 0.34
▸ ADORA1 P30542 2/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ PDE10A Q9Y233 2/20 0.34
▸ CSNK1E P49674 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14896977 0.89 AAK1 (0.40) MCHR1HRH4HRH3AAK1MAPK8
SCHEMBL14897164 0.89 MCHR1 (0.40) MCHR1HRH4HRH3MAP4K4AAK1
SCHEMBL14897709 0.89 CSNK1E (0.36) KCNH2CSNK1E
SCHEMBL14897567 0.86 HRH4 (0.43) MCHR1HRH4HRH3MAP4K4AAK1
SCHEMBL14897434 0.85 AAK1 (0.39) MCHR1HRH4HRH3AAK1
SCHEMBL20356798 0.85 AAK1 (0.39) MCHR1HRH4HRH3AAK1
SCHEMBL14896905 0.84 AAK1 (0.38) MCHR1HRH4HRH3AAK1MAPK8
SCHEMBL16193168 0.84 IRAK4 (0.45) MCHR1HRH4HRH3MAP4K4AAK1
SCHEMBL14897431 0.83 ATR (0.38) MCHR1HRH4HRH3AAK1KCNH2
SCHEMBL14897272 0.83 MCHR1 (0.42) MCHR1AAK1MAPK8MAPK10BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-2768509-B1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2017-03-22 — — EP disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
WO-2013059587-A9 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2014-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 MCHR1 3729/4885HRH4 3580/4885HRH3 3664/4885
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 MCHR1 3729/4885HRH4 3580/4885HRH3 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback